Introduction {#s0005}
============

In South Korea, biliary tract cancers (BTCs), including cholangiocarcinoma and gallbladder cancer (GBC), are not uncommon [@bb0005]. Due to the non-specific symptoms associated with BTCs, more than 75% of cases are unresectable because of the advanced stage of disease at diagnosis. Moreover, even after a complete resection, many patients experience a recurrence of disease. Patients with advanced or recurrent BTCs can be considered for palliative chemotherapy [@bb0010], [@bb0015]. Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard first-line chemotherapy for advanced BTC, based on the results of previous randomized phase II and III trials (ABC01 and 02) [@bb0020], [@bb0025]. Nevertheless, prognosis is still poor and overall survival (OS) is less than 12 months in patients with advanced or recurrent BTCs [@bb0025].

Molecularly targeted therapies, either given alone or in combination with chemotherapy, have emerged as the standard treatment for a variety of cancer types [@bb0030], [@bb0035]. These therapies have been applied to treatment of BTCs. Erlotinib is an orally active tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), which has been associated with improved outcomes in various cancers [@bb0040]. Erlotinib, alone or in combination, has shown promising results in phase II trials in patients with advanced BTC, with response rates (RRs) of 8% to 12%, median OS of 7.5 to 9.9 months, and median time to progression of 2.6 to 4.4 months [@bb0045], [@bb0050]. In our phase III trial (NCT01149122) of gemcitabine and oxaliplatin (GEMOX) with or without erlotinib, the median progression-free survival (PFS) was 4.2 months in the GEMOX group and 5.8 months in the GEMOX plus erlotinib group [@bb0055]. Results of this phase III trial suggested that the addition of erlotinib to GEMOX might be a new treatment option for patients with cholangiocarcinoma, although no significant difference in PFS was noted between the groups.

BTCs have a spectrum of mutations in EGFR and its downstream signaling pathways, which include *EGFR*, *KRAS*, and *PIK3CA* [@bb0060], [@bb0065], [@bb0070], [@bb0075]. The EGFR signaling pathway has been extensively explored for several years as a therapeutic target for cancer therapy. Dysregulation of EGFR signaling has been shown to stimulate cell proliferation, angiogenesis, and metastatic spread while inhibiting apoptosis. It is well known that oncogenic activation of *EGFR* and its downstream pathways, including *KRAS*, *BRAF*, *PTEN*, *PIK3CA*, and *AKT*, is correlated with responsiveness to anti-EGFR therapies [@bb0080], [@bb0085]. Given the evidence that *KRAS* mutations are associated with less efficient EGFR-directed targeted therapy in various cancer types [@bb0090], [@bb0095], we evaluated *KRAS* mutation status in 60 of 268 patients who were enrolled in our previous phase III trial [@bb0055]. However, the predictive value of *KRAS* mutation for response to erlotinib was limited by the small number of tissues we analyzed.

Herein, to clarify the roles of *EGFR*, *KRAS*, and *PIK3CA* as predictive biomarkers in patients with advanced BTC who received erlotinib, we investigated the mutational status of tumors from archival specimens in an expanded subset of patients enrolled on our study.

Patients and Methods {#s0020}
====================

Patients and Samples {#s0025}
--------------------

Eligibility criteria and study design have been previously described. This was an open-label, randomized, phase III trial comparing erlotinib plus GEMOX with GEMOX alone as a first-line treatment for advanced BTCs [@bb0055]. The primary endpoint was PFS and analyses were conducted by intention to treat (ITT). The study included 268 randomized patients and a separate written consent for the optional correlative study was obtained to allow participation in the exploratory biomarker study of archival tumor specimens. Specimens were labeled with site of origin and a unique patient identifier. Sixty-four patients (48.1%) were available for mutational analysis in the chemotherapy alone group (*n* = 131) and 61 (45.1%) in the chemotherapy plus erlotinib group (*n* = 135).

DNA Extraction and Mutation Analysis for EGFR, KRAS, and PIK3CA {#s0030}
---------------------------------------------------------------

DNA was extracted from five 10-μm formalin-fixed paraffin-embedded sections containing a representative portion of each tumor block, using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). A pathologist (K.-T.J.) reviewed each slide and verified the presence of adequate tumor tissue with greater than 50% representative malignant cells.

Peptide nucleic acid (PNA)--locked nucleic acid polymerase chain reaction (PCR) clamp reactions were carried out using the PNA-Clamp *EGFR*, PNA-Clamp *KRAS*, and PNA-Clamp *PIK3CA* Mutation Detection kits (Panagene, Inc, Daejeon, Korea), as described previously [@bb0100], [@bb0105]. Briefly, this reaction consists of the following: all reactions were done in 20-μl volumes using 10 to 25 ng of template DNA, primer and PNA probe set, and SYBR Green PCR master mix. All necessary reagents are included with the kit. Real-time PCR reactions of PNA-mediated clamping PCR were performed using a CFX 96 System (Bio-Rad, Foster City, California). PCR cycling conditions were a 5-minute holding period at 94°C, followed by 40 cycles of 94°C for 30 seconds, 70°C for 20 seconds, 63°C for 30 seconds, and 72°C for 30 seconds. Detection of each of the 29 mutations in *EGFR* exons 18 to 21, 7 mutations in *KRAS* exon 2, and 3 mutations in *PIK3CA* exons 2 and 9 was possible using one-step PNA-mediated real-time PCR clamping.

Statistical Analysis {#s0035}
--------------------

PFS, OS, and overall RR were evaluated with respect to tumor mutation status (*KRAS* and *PIK3CA*). PFS and OS were analyzed by the Kaplan-Meier method and stratified log-rank test. The predefined variables used to investigate the association of potential prognostic factors for PFS were age, sex, primary site, differentiation, disease status, liver-only metastasis, number of involved sites, the use of erlotinib, *KRAS* mutation status, *PIK3CA* mutation status, and any mutation of *EGFR*, *KRAS*, or *PIK3CA*. The Cox proportional hazards model was used for univariate and multivariate analyses to assess the independent effects of variables and to obtain their Hazard Ratio (HR estimates). *P* \< .05 values were considered significant.

Results {#s0010}
=======

Patients and Samples {#s0040}
--------------------

In our previous study that included 268 patients randomly assigned to receive GEMOX plus erlotinib (*N* = 133) or GEMOX alone (*N* = 135), 227 events were observed over a median follow-up time of 15 months (range, 11.0-18.9 months) [@bb0055].

In the initial analysis, we were able to analyze either EGFR overexpression or KRAS mutation status from 60 tissue specimens (22.3% of the ITT population) that had sufficient DNA ([Figure 1](#f0005){ref-type="fig"}). In contrast, a total of 125 tissue specimens (mutation analysis population; 46.6% of the ITT population) was included for current analysis ([Figure 1](#f0005){ref-type="fig"}).Figure 1Consort.

The baseline characteristics were well balanced between the treatment groups in the ITT and mutation analysis population ([Table 1](#t0005){ref-type="table"}). In the mutation analysis population (*N* = 125), 64 patients (51.2%) received GEMOX alone and 61 (48.9%) received GEMOX plus erlotinib.Table 1Characteristics of 125 Advanced BTC Patients Treated with GEMOX with or without ErlotinibITT PopulationMutation Analysis PopulationGEMOX (*n* = 133)GEMOX Plus Erlotinib (*n* = 135)GEMOX (*n* = 64)GEMOX Plus Erlotinib (*n* = 61)Age, years Median61 (55-68)59 (54-66)61 (45-77)58 (39-77)Sex Male79 (59%)91 (67%)42 (65.6%)39 (63.9%) Female54 (41%)44 (33%)22 (34.4%)22 (36.1%)Primary site Cholangiocarcinoma (intra-hepatic and extra-hepatic)84 (63%)96 (71%)43 (67.2%)44 (72.1%) Gallbladder47 (35%)35 (26%)20 (31.3%)14 (23.0%) AoV2 (2%)4 (3%)1 (1.6%)3 (4.9%)Differentiation Well6 (5%)11 (8%)3 (4.7%)7 (11.5%) Moderate92 (69%)91 (67%)36 (56.3%)28 (45.9%) Poorly or unknown35 (26%)33 (24%)25 (39.1%)26 (42.6%)EOCG performance status 020 (15%)26 (19%)5 (7.8%)7 (11.5%) 1100 (75%)104 (77%)56 (87.5%)54 (88.5%) 213 (10%)5 (4%)1 (1.6%)-Disease status Recurrent23 (17%)31 (23%)16 (25.0%)22 (36.1%) Primarily metastatic110 (83%)104 (77%)48 (75.0%)39 (63.9%)Liver-only metastasis Yes46 (35%)42 (31%)13 (20.3%)10 (16.4%) No87 (65%)93 (69%)51 (79.7%)51 (83.6%)Number of metastatic sites 182 (62%)84 (62%)52 (81.3%)52 (85.2%) 2 ≤51 (38%)51 (38%)12 (18.8%)9 (14.7%)

Frequency of EGFR, KRAS, and PIK3CA Mutations {#s0045}
---------------------------------------------

The mutational status of *EGFR*, *KRAS*, and *PIK3CA* was identifiable in 116, 121, and 118 patients, respectively. *EGFR* mutations were found in 2 of 116 patients (1.7%). Two cholangiocarcinoma patients harbored *EGFR T790M* mutations and were treated with GEMOX alone. Following chemotherapy, one of these patients showed a complete response, while the second patient maintained stable disease. The incidence of *KRAS* mutations was 9.9% \[12 of 121, 4 GBCs, 7 cholangiocarcinomas, and 1 Ampulla of Vater (AoV) cancer\]. Most *KRAS* mutations occurred at codon 12 (11 of 12 patients, 91.6%). *PIK3CA* mutations, which were observed in 12 of 118 patients (10.1%), occurred mainly in exons 9 (10 patients) and 10 (2 patients). All patients with *PIK3CA* mutations had cholangiocarcinoma ([Table 2](#t0010){ref-type="table"}). Mutations in both *KRAS* and *PIK3CA* were found in the tumor tissues from three patients.Table 2Mutational Spectrum of EGFR, KRAS, and PIK3CAGeneGallbladder, *n* = 34, (%)Cholangiocarcinoma, *n* = 87, (%)AoV, *n* = 4, (%)*EGFR*0 (0.0%)2 (2.3%)0 (0.0%) T790M0 (0.0%)2 (2.3%)0 (0.0%)*KRAS*4 (11.7%)7 (8.0%)1 (25%) Codon 124 (11.7%)6 (6.9%)1 (25%) Codon 130 (0.0%)1 (1.1%)0 (0.0%)*PIK3CA*0 (0.0%)12 (13.8%)0 (0.0%) E5420 (0.0%)3 (3.5%)0 (0.0%) E5450 (0.0%)7 (8.0%)0 (0.0%) H10470 (0.0%)2 (2.3%)0 (0.0%)

Impact of Mutation of KRAS and PIK3CA on Clinical Outcomes {#s0050}
----------------------------------------------------------

The statistical significances (*P* value) for RR, PFS, and OS in the ITT and mutational analysis populations were comparable ([Table 3](#t0015){ref-type="table"}). Patients with wild-type *KRAS* tumors who received erlotinib plus GEMOX (GEMOXT) had significantly increased overall RR compared with those who received GEMOX alone ([Table 3](#t0015){ref-type="table"}). However, there was no significant difference in RR in patients with *KRAS* mutations between the GEMOX with and without erlotinib treatment groups. In patients whose tumors carried wild-type *PIK3CA*, erlotinib plus GEMOX showed a favorable trend for overall response, but no statistically significance difference (*P* = .08). In 95 patients with both wild-type *KRAS* and *PIK3CA*, there was evidence of a benefit associated with the addition of erlotinib to GEMOX in relation to RR as compared with GEMOX alone (*P* = .04). No significant difference was observed in PFS and OS between the treatment groups, irrespective of *KRAS* or *PIK3CA* mutation status. Additionally, in 92 patients with wild-type *EGFR*, *KRAS*, and *PIK3CA*, the addition of erlotinib to GEMOX improved tumor responses (*P* = .03; [Table 3](#t0015){ref-type="table"}).Table 3Efficacy of GEMOX with or without Erlotinib according to the Mutational StatusITT Population (*n* = 268)Mutation Analysis Population (*n* = 125)KRAS Mutation Status (*n* = 121)PIK3CA Mutation Status (*n* = 118)Overall Mutation Status (*n* = 114)KRAS Wild (*n* = 109)KRAS Mutant (*n* = 12)PIK3CA Wild (*n* = 106)PIK3CA Mutant (*n* = 12)No Mutation[⁎](#tf0005){ref-type="table-fn"} (*n* = 92)Any Mutant[†](#tf0010){ref-type="table-fn"} (*n* = 22)GEMOXGEMOXTGEMOXGEMOXTGEMOXGEMOXTGEMOXGEMOXTGEMOXGEMOXTGEMOXGEMOXTGEMOXGEMOXTGEMOXGEMOXTRR16%30%15.6%31.1%12.5%30.2%60%28.6%14.8%28.8%14.3%60.0%12.7%31.1%25.0%40.0%0.0050.0400.0240.5580.0800.2220.0330.452DCR67%66%65.6%62.3%66.1%60.4%60%71.4%66.7%61.5%57.1%80.0%68.0%60.0%58.3%80.0%-0.6980.5381.0000.5820.5760.4190.381PFS4.2 months5.8 months2.7 months6.2 months2.7 months6.6 months11.5 months3.1 months2.9 months6.2 months2.1 months7.3 months4.0 months6.4 months2.1 months4.1 months0.0870.1720.1250.5010.1800.8580.2960.735OS9.5 months9.5 months8.0 months9.7 months8.0 months9.1 monthsNA months10.7 months8.5 months9.7 months4.0 months10.7 months8.5 months8.5 months7.2 months10.7 months0.6110.4150.4490.5090.6740.5470.7660.742[^1][^2][^3]

In the mutation analysis population (*n* = 125), the estimated median PFS time was 4.8 months \[95% confidence interval (CI), 3.2-6.4\]. Median PFS was not significantly different in either treatment group \[2.7 months (95% CI, 1.3-4.1) in GEMOX alone group and 6.2 months (95% CI, 4.5-7.8) in GEMOX plus erlotinib group, *P* = .172; [Figure 2](#f0010){ref-type="fig"}\]. There was also no significant difference in PFS between the GEMOX with and without erlotinib groups in either patients with wild-type *EGFR/KRAS/PIK3CA* or with any mutation in *EGFR* or *KRAS* or *PIK3CA* ([Figure 3](#f0015){ref-type="fig"}). Univariate analysis revealed that PFS was not associated with the addition of erlotinib to chemotherapy, mutation status of *KRAS* and *PIK3CA*, and wild-type status of *EGFR/KRAS/PIK3CA* ([Table 4](#t0020){ref-type="table"}).Figure 2PFS. (A) Overall and (B) according to GEMOX with or without erlotinib.Figure 3PFS according to GEMOX with or without erlotinib in patients with (A) EGFR/KRAS/PIK3CA wild type and (B) any mutation of EGFR or KRAS or PIK3CA.Table 4Prognostic Factors for PFS in Univariate AnalysisCharacteristicsMedian PFS (95% CI), MonthsUnivariateHR (95% CI)*P*Age0.880 (0.606-1.278).502 ≤ 605.93 (3.57-8.28) \> 604.00 (1.62-6.37)Sex0.942 (0.775-1.144).546 Male4.17 (2.30-6.03) Female5.93 (3.90-7.95)Primary sites1.003 (0.666-1.510).989 Cholangiocarcinoma4.90 (3.13-6.66) GBC/AoV cancer3.63 (0.05-7.20)Differentiation1.114 (0.763-1.626).578 Well/moderate4.57 (1.61-7.52) Poorly4.90 (2.43-7.36)Disease status1.406 (0.928-2.130).108 Recurrent6.60 (3.77-9.42) Primarily metastatic4.17 (1.93-6.40)Liver-only metastasis1.239 (0.761-2.018).388 Yes3.87 (1.72-6.01) No4.90 (3.09-6.70)Number of metastatic sites0.969 (0.600-1.562).896 14.30 (2.38-6.21) 2 ≤6.00 (3.45-8.54)GEMOX0.772 (0.532-1.122).175 Without erlotinib2.77 (1.34-4.19) With erlotinib6.20 (4.52-7.87)KRAS0.846 (0.427-1.626).631 Wild type4.90 (3.04-6.76) Mutant type3.17 (0.00-7.31)PIK3CA0.974 (0.519-1.828).934 Wild type5.10 (3.25-6.95) Mutant type3.00 (0.00-6.46)Mutation status1.095 (0.662-1.812).723 EGFR/KRAS/PIK3CA wild5.10 (3.19-7.00) Any mutation3.17 (0.36-5.97)

Discussion {#s0015}
==========

Emerging evidence has implicated the EGFR pathway as a potential therapeutic target in BTC [@bb0110], [@bb0115]. Oncogenic activation of the EGFR pathway, including EGFR-RAS-RAF or EGFR-PIK3CA signaling, is a key mechanism in the efficacy of EGFR-directed therapy [@bb0080]. Presently, we do not know the biologic significance of mutations in these genes or to what extent they confer sensitivity to currently available small-molecule inhibitors, including erlotinib, in BTCs. We have previously analyzed the efficacy of chemotherapy plus erlotinib with respect to *KRAS* status using data from our previous phase III trial for BTC. Clinical samples from which tumor DNA could be successfully analyzed were initially available for a subset of 22.3% of the ITT population. Subsequently, through the use of improved ascertainment, the total number of patients from whom tumor *KRAS* mutation status could be assessed was approximately doubled to 46.6% of the ITT population (mutation analysis population). Moreover, mutation status for *EGFR* and *PIK3CA* was analyzed in this mutation analysis population. Herein, we report the impact of the mutation status of *EGFR*, *KRAS*, and *PIK3CA* on the clinical outcomes of patients treated with a small-molecule inhibitor of the EGFR kinase domain in an expanded patient cohort.

This analysis suggested that *KRAS* mutation might be a predictor of resistance to the small-molecule inhibitor erlotinib in BTCs. It is yet unknown if *KRAS* mutation in BTCs is a negative predictor of the effectiveness of anti-EGFR treatment. In colorectal cancer, it has been established that *KRAS* mutation precludes any therapeutic benefit from anti-EGFR antibodies (cetuximab and panitumumab) [@bb0120], [@bb0125]. In addition, we have also published that *KRAS* mutations might be negative predictive biomarkers in advanced pancreatic cancer patients who have been treated with a gemcitabine-erlotinib combination [@bb0130]. In contrast, this concept has not yet been confirmed in other types of cancer including BTCs. Gruenberger et al. investigated the efficacy of gemcitabine, oxaliplatin, and cetuximab combinations in patients with advanced BTCs and reported that two of three patients harboring *KRAS* mutations showed a partial response to cetuximab plus chemotherapy [@bb0135]. We also analyzed *KRAS* mutations in the 60 specimens in our study and showed that three of six patients with *KRAS* mutations responded to erlotinib [@bb0055]. These findings suggest that anti-EGFR therapies might be beneficial, irrespective of *KRAS* mutational status, in BTCs. However, our sample size was too small to allow us to draw any significant conclusions. There is a discrepancy between our current findings and previous reports, which may have resulted from our small sample size, geographic differences, different testing techniques, and heterogeneity of the patient populations between studies [@bb0055], [@bb0135]. Although our present analysis used a larger sample set as compared with previous analyses, the sample size of this study was still too small.

Additionally, we found that *PIK3CA* mutation was also associated with a lack of erlotinib activity in BTCs that retain wild-type *KRAS*. *PIK3CA* mutations, which are commonly found in colon, breast, gastric, and brain cancers, are rarely found in BTC [@bb0075]. *PIK3CA* mutations mainly occur in exons 9 (E542K, E545K) and 20 (H1047R) [@bb0090], [@bb0140], [@bb0145]. In our analysis, 12 patients had PIK3CA mutations, with 10 having a mutation in exon 9 and 2 in exon 20. Of the 12 patients with *PIK3CA* mutation, 3 patients also had a *KRAS* mutation. In the 95 patients with both wild-type *KRAS* and *PIK3CA*, there was evidence of a benefit associated with the addition of erlotinib to GEMOX, as compared with GEMOX alone, with respect to RR (*P* = .04). However, in 9 patients with wild-type KRAS and PIK3CA mutations (8 in exon 9 and 1 in exon 20), the addition of erlotinib to chemotherapy did not result in an improved response (*P* = .08). The effect of the mutation status of *PIK3CA* on anti-EGFR therapies has been studied in *KRAS* wild-type colorectal cancers [@bb0065], [@bb0090], [@bb0150], [@bb0155]. To the best of our knowledge, this is the first report to evaluate the correlation between the mutation status of PIK3CA and the activity of the anti-EGFR therapy erlotinib in BTCs. Clearly, however, the role of KRAS and PIK3CA mutations in response to treatment with anti-EGFR agents needs further analysis in a larger homogeneous population.

EGFR mutations occur in a significant minority of patients (13-15%) with BTC; however, the results of mutation analyses from two studies were quite different [@bb0065], [@bb0070]. In our study, EGFR mutation was found in 2 of 116 patients (1.7%). These two patients harbored an *EGFR T790M* mutation that is known to confer resistance to currently available small-molecule inhibitors. This EGFR T790M mutation was not described in previous studies [@bb0065], [@bb0070].

Our analysis revealed that *KRAS* mutational status might be considered a negative predictive biomarker for response to erlotinib in BTCs. Additionally, the mutation status of *PIK3CA* may be a determinant in the decision as to whether to add erlotinib to chemotherapy in *KRAS* wild-type BTCs. However, tissue availability was a potential limitation of the current retrospective mutational analysis. This is as critical an issue in BTC research as it is in pancreatic cancer. In the current study, about 20% of patients in the ITT population underwent prior surgery, as did about 30% of patients in the mutation analysis population, thereby effectively limiting the availability and adequacy of surgical specimens for biomarker analysis. Therefore, possible selection bias in the current study may make definitive conclusions difficult and may have influenced the prognostic and predictive results of *KRAS* and *PIK3CA* status, which need to be interpreted with caution and validated. Further prospective studies are needed for defining predictive or prognostic biomarkers. The rarity of BTC hinders clinicians from conducting definitive trials and from producing rigorous scientific data. Thus, coordination of trials among institutions and cooperative groups, both nationally and internationally, will be the key to improving treatment outcomes in BTCs. Additionally, because of the heterogeneity of BTCs, appropriate stratification using clinical or molecular factors will help to define more clearly outcomes of the research.
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[^1]: DCR; Disease Conrol Rate.

[^2]: Wild type for all EGFR, KRAS, and PIK3CA

[^3]: Any mutant type for EGFR, KRAS, or PIK3C
